These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1398260)

  • 1. Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment.
    Vercellini P; Vendola N; Colombo A; Passadore C; Trespidi L; Crosignani PG
    Gynecol Obstet Invest; 1992; 34(2):102-4. PubMed ID: 1398260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study.
    Vercellini P; Sacerdote P; Trespidi L; Manfredi B; Panerai AE; Crosignani PG
    Fertil Steril; 1994 Nov; 62(5):938-42. PubMed ID: 7926138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women.
    Melis GB; Gambacciani M; Cagnacci A; Paoletti AM; Mais V; Fioretti P
    Obstet Gynecol; 1988 Nov; 72(5):688-92. PubMed ID: 3140150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Veralipride in the treatment of hot flushes in the menopause].
    Pasetto N; Piccione E; Baschieri L
    Rev Fr Gynecol Obstet; 1985 Feb; 80(3):163-5. PubMed ID: 3922035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Veralipride: alternative antidopaminergic treatment for menopausal symptoms.
    David A; Don R; Tajchner G; Weissglas L
    Am J Obstet Gynecol; 1988 May; 158(5):1107-15. PubMed ID: 2967034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of veralipride on LH, FSH, and PRL levels and on the climacteric syndrome].
    De Cecco L; Venturini PL; Alibrandi MP; Grondona AL; Morano S; Penna L; Campanella G; Ragni N
    Rev Fr Gynecol Obstet; 1985 Feb; 80(3):152-5. PubMed ID: 3922034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
    Howell R; Edmonds DK; Dowsett M; Crook D; Lees B; Stevenson JC
    Fertil Steril; 1995 Sep; 64(3):474-81. PubMed ID: 7641897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness and tolerance of a gonadotropin releasing hormone (goserelin) in treatment of symptomatic endometriosis].
    Wenzl R; Schultes G; Stummvoll W; Wieser F; Husslein P
    Wien Klin Wochenschr; 1999 Apr; 111(7):283-8. PubMed ID: 10355039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women.
    Morgante G; Farina M; Cianci A; La Marca A; Petraglia F; De Leo V
    Gynecol Endocrinol; 2004 Apr; 18(4):194-8. PubMed ID: 15293890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis.
    Taskin O; Yalcinoglu AI; Kucuk S; Uryan I; Buhur A; Burak F
    Fertil Steril; 1997 Jan; 67(1):40-5. PubMed ID: 8986681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results.
    Venturini PL; Fasce V; Costantini S; Anserini P; Cucuccio S; de Cecco L
    Fertil Steril; 1990 Dec; 54(6):1021-7. PubMed ID: 2147154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Veralipride and menopause].
    Laffargue F; Viala JL; Durand G
    Sem Hop; 1983 Sep; 59(29-30):2127-30. PubMed ID: 6312585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.
    Vercellini P; Trespidi L; Colombo A; Vendola N; Marchini M; Crosignani PG
    Fertil Steril; 1993 Jul; 60(1):75-9. PubMed ID: 8513962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and hormonal effects of long-term veralipride treatment in post-menopausal women.
    Verbeke K; Dhont M; Vandekerckhove D
    Maturitas; 1988 Oct; 10(3):225-30. PubMed ID: 3185294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The failed suppression of serum estradiol level by gonadotropin-releasing hormone agonist in a case of pelvic endometriosis.
    Tamaya T; Misao R; Nakanishi Y
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 1):828-9. PubMed ID: 9758002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate.
    Cedars MI; Lu JK; Meldrum DR; Judd HL
    Obstet Gynecol; 1990 Apr; 75(4):641-5. PubMed ID: 2138265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of GnRH agonist treatment on 3-5 days postoperatively in endometriosis patients: a randomized controlled trial.
    Gong L; Zhang S; Han Y; Long Q; Zou S; Cao Y
    J Clin Pharmacol; 2015 Aug; 55(8):848-53. PubMed ID: 25694383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
    Gregoriou O; Konidaris S; Vitoratos N; Papadias C; Papoulias I; Chryssicopoulos A
    Int J Fertil Womens Med; 1997; 42(6):406-11. PubMed ID: 9459084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of veralipride.
    De Leo V; Morgante G; Musacchio MC; Faldini E; Delia A; Petraglia F
    Expert Opin Drug Saf; 2006 Sep; 5(5):695-701. PubMed ID: 16907659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the antidopaminergic drug veralipride on LH and PRL secretion in postmenopausal women.
    Fioretti P; Cagnacci A; Paoletti AM; Gambacciani M; Soldani R; Mauro GA; Spinetti A; Melis GB
    J Endocrinol Invest; 1989 May; 12(5):295-301. PubMed ID: 2549113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.